The novel combination of astragaloside IV and formononetin protects from doxorubicin-induced cardiomyopathy by enhancing fatty acid metabolism

Abstract

Astragali Radix (AR), a traditional Chinese medicine (TCM), has demonstrated therapeutic efficacy against various diseases, including cardiovascular conditions, over centuries of use. While doxorubicin serves as an effective chemotherapeutic agent against multiple cancers, its clinical application remains constrained by significant cardiotoxicity. Research has indicated that AR exhibits protective properties against doxorubicin-induced cardiomyopathy (DIC); however, the specific bioactive components and underlying mechanisms responsible for this therapeutic effect remain incompletely understood. This investigation seeks to identify the protective bioactive components in AR against DIC and elucidate their mechanisms of action. Through network medicine analysis, astragaloside IV (AsIV) and formononetin (FMT) were identified as potential cardioprotective agents from 129 AR components. In vitro experiments using H9c2 rat cardiomyocytes revealed that the AsIV-FMT combination (AFC) effectively reduced doxorubicin-induced cell death in a dose-dependent manner, with optimal efficacy at a 1∶2 ratio. In vivo, AFC enhanced survival rates and improved cardiac function in both acute and chronic DIC mouse models. Additionally, AFC demonstrated cardiac protection while maintaining doxorubicin’s anti-cancer efficacy in a breast cancer mouse model. Lipidomic and metabolomics analyses revealed that AFC normalized doxorubicin-induced lipid profile alterations, particularly by reducing fatty acid accumulation. Gene knockdown studies and inhibitor experiments in H9c2 cells demonstrated that AsIV and FMT upregulated peroxisome proliferator activated receptor γ coactivator 1α (PGC-1α) and PPARα, respectively, two key proteins involved in fatty acid metabolism. This research establishes AFC as a promising therapeutic approach for DIC, highlighting the significance of multi-target therapies derived from natural herbals in contemporary medicine.

Keywords

Astragali Radix / Lipidomics / Anthracyclines / Cardio-oncology / Combination therapy

References

[1] Sallustio BC, Boddy AV. Is there scope for better individualisation of anthracycline cancer chemotherapy? Brit J Clin Pharmaco. 2021; 87(2):295-305. https://doi.org/10.1111/bcp.14628.

[2] Moslehi J. Cardiovascular toxic effects of targeted cancer therapies. N Engl J Med. 2016; 375(15):1457-1467. https://doi.org/10.1056/NEJMra1100265.

[3] Skok Z, Zidar N, Kikelj D, et al. Dual inhibitors of human DNA topoisomerase II and other cancer-related targets. J Med Chem. 2020; 63(3):884-904. https://doi.org/10.1021/acs.jmedchem.9b00726.

[4] Christidi E, Brunham LR. Regulated cell death pathways in doxorubicin-induced cardiotoxicity. Cell Death Dis. 2021; 12(4):339. https://doi.org/10.1038/s41419-021-03614-x.

[5] Szczepaniak P, Siedlinski M, Hodorowicz-Zaniewska D, et al. Breast cancer chemotherapy induces vascular dysfunction and hypertension through NOX4 dependent mechanism. J Clin Investig. 2022; 132(13):e149117. https://doi.org/10.1172/JCI149117.

[6] Yu X, Ruan Y, Shen T, et al. Dexrazoxane protects cardiomyocyte from doxorubicin-induced apoptosis by modulating miR-17-5p. BioMed Res Int. 2020;2020:5107193. https://doi.org/10.1155/2020/5107193.

[7] Seif AE, Walker DM, Li Y, et al. Dexrazoxane exposure and risk of secondary acute myeloid leukemia in pediatric oncology patients. Pediatr Blood Cancer. 2015; 62(4):704-709. https://doi.org/10.1002/pbc.25043.

[8] Chow EJ, Aggarwal S, Doody DR, et al. Dexrazoxane and long-term heart function in survivors of childhood cancer. J Clin Oncol. 2023; 41(12):2248-2257. https://doi.org/10.1200/JCO.22.02423.

[9] Wu L, Wang L, Du Y, et al. Mitochondrial quality control mechanisms as therapeutic targets in doxorubicin-induced cardiotoxicity. Trends Pharmacol Sci. 2023; 44(1):34-49. https://doi.org/10.1016/j.tips.2022.10.003.

[10] Yamamoto T, Sano M. Deranged myocardial fatty acid metabolism in heart failure. Int J Mol Sci. 2022; 23(2):996. https://doi.org/10.3390/ijms23020996.

[11] Liu Y, Zeng L, Yang Y, et al. Acyl-CoA thioesterase 1 prevents cardiomyocytes from doxorubicin-induced ferroptosis via shaping the lipid composition. Cell Death Dis. 2020; 11(9):756. https://doi.org/10.1038/s41419-020-02948-2.

[12] Chen W, Zhao H, Li Y. Mitochondrial dynamics in health and disease: mechanisms and potential targets. Signal Transduct Target Ther. 2023; 8(1):333. https://doi.org/10.1038/s41392-023-01547-9.

[13] Qian L, Zhu Y, Deng C, et al. Peroxisome proliferator-activated receptor gamma coactivator-1 (PGC-1) family in physiological and pathophysiological process and diseases. Signal Transduct Target Ther. 2024; 9(1):50. https://doi.org/10.1038/s41392-024-01756-w.

[14] Zhou X, Liu Y, Shen Y, et al. Rescue of cardiac dysfunction during chemotherapy in acute myeloid leukaemia by blocking IL-1α. Eur Hear J. 2024; 00:1-16. https://doi.org/10.1093/eurheartj/ehae188.

[15] Li M, Han B, Zhao H, et al. Biological active ingredients of Astragali Radix and its mechanisms in treating cardiovascular and cerebrovascular diseases. Phytomedicine. 2022;98:153918. https://doi.org/10.1016/j.phymed.2021.153918.

[16] Chen Z, Liu L, Gao C, et al. Astragali Radix (Huangqi): a promising edible immunomodulatory herbal medicine. J Ethnopharmacol. 2020;258:112895. https://doi.org/10.1016/j.jep.2020.112895.

[17] Han Z, Guo L, Yu X, et al. Network-driven targeted analysis reveals that Astragali Radix alleviates doxorubicin-induced cardiotoxicity by maintaining fatty acid homeostasis. J Ethnopharmacol. 2022;287:114967. https://doi.org/10.1016/j.jep.2022.114967.

[18] Li K, Zhang R, Li SY, et al. Potential quality evaluation approach for the absolute growth years’ wild and transplanted Astragali Radix based on anti-heart failure efficacy. Chin J Nat Med. 2020; 18(6):460-471. https://doi.org/10.1016/S1875-5364(20)30053-4.

[19] Lin J, Fang L, Li H, et al. Astragaloside IV alleviates doxorubicin induced cardiomyopathy by inhibiting NADPH oxidase derived oxidative stress. Eur J Pharmacol. 2019;859:172490. https://doi.org/10.1016/j.ejphar.2019.172490.

[20] Wang P, Wang Z, Zhang Z, et al.A review of the botany, phytochemistry, traditional uses, pharmacology, toxicology, and quality control of the Astragalus memeranaceus. Front Pharmacol. 2023;14:1242318. https://doi.org/10.3389/fphar.2023.1242318.

[21] Zhai J, Tao L, Zhang S, et al. Calycosin ameliorates doxorubicin‐induced cardiotoxicity by suppressing oxidative stress and inflammation via the sirtuin 1-NOD-like receptor protein 3 pathway. Phytother Res. 2020; 34(3):649-659. https://doi.org/10.1002/ptr.6557.

[22] Xuan Q, Hu C, Yu D, et al. Development of a high coverage pseudotargeted lipidomics method based on ultra-high performance liquid chromatography-mass spectrometry. Anal Chem. 2018; 90(12):7608-7616. https://doi.org/10.1021/acs.analchem.8b01331.

[23] Wu J, Deng S, Yu X, et al. Identify production area, growth mode, species, and grade of Astragali Radix using metabolomics “big data” and machine learning. Phytomedicine. 2024;123:155201. https://doi.org/10.1016/j.phymed.2023.155201.

[24] Guney E, Menche J, Vidal M, et al. Network-based in silico drug efficacy screening. Nat Commun. 2016; 7(1):10331. https://doi.org/10.1038/ncomms10331.

[25] Gysi DM, Valle Í do, Zitnik M, et al.Network medicine framework for identifying drug-repurposing opportunities for COVID-19. P Natl Acad Sci USA. 2021; 118(19):e2025581118. https://doi.org/10.1073/pnas.2025581118.

[26] Duarte D, Vale N. Evaluation of synergism in drug combinations and reference models for future orientations in oncology. Curr Res Pharmacol Drug Discov. 2022;3:100110. https://doi.org/10.1016/j.crphar.2022.100110.

[27] Menche J, Sharma A, Kitsak M, et al. Uncovering disease-disease relationships through the incomplete interactome. Science. 2015; 347(6224):1257601. https://doi.org/10.1126/science.1257601.

[28] Zhang W, Wang S, Kang C, et al. Pharmacodynamic material basis of traditional Chinese medicine based on biomacromolecules: a review. Plant Methods. 2020;16:26. https://doi.org/10.1186/s13007-020-00571-y.

[29] Montaigne D, Butruille L, Staels B. PPAR control of metabolism and cardiovascular functions. Nat Rev Cardiol. 2021; 18(12):809-823. https://doi.org/10.1038/s41569-021-00569-6.

[30] Zhang T, Xu L, Guo X, et al. The potential of herbal drugs to treat heart failure: the roles of Sirt1/AMPK. J Pharm Anal. 2024; 14(2):157-176. https://doi.org/10.1016/j.jpha.2023.09.001.

[31] Qu J, Ke F, Yang X, et al. Induction of P-glycoprotein expression by dandelion in tumor and heart tissues: impact on the anti-tumor activity and cardiotoxicity of doxorubicin. Phytomedicine. 2022;104:154275. https://doi.org/10.1016/j.phymed.2022.154275.

[32] Zhou Y, Fang J, Bekris L M, et al. AlzGPS: a genome-wide positioning systems platform to catalyze multi-omics for Alzheimer’s drug discovery. Alzheimer’s Res Ther. 2021;13:24. https://doi.org/10.1186/s13195-020-00760-w.

[33] Zhou Y, Hou Y, Shen J, et al.Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2. Cell Discov. 2020;6:14. https://doi.org/10.1038/s41421-020-0153-3.

[34] Tadokoro T, Ikeda M, Ide T, et al. Mitochondria-dependent ferroptosis plays a pivotal role in doxorubicin cardiotoxicity. JCI Insight. 2020; 5(9):e132747. https://doi.org/10.1172/jci.insight.132747.

[35] Lin Y, Liu R, Huang Y, et al. Reactivation of PPARα alleviates myocardial lipid accumulation and cardiac dysfunction by improving fatty acid β-oxidation in Dsg2-deficient arrhythmogenic cardiomyopathy. Acta Pharm Sin B. 2023; 13(1):192-203. https://doi.org/10.1016/j.apsb.2022.05.018.

[36] Zhang C, Chang X, Zhao D, et al. Mitochondria and myocardial ischemia/reperfusion injury: effects of Chinese herbal medicine and the underlying mechanisms. J Pharm Anal. 2024:101051. https://doi.org/10.1016/j.jpha.2024.101051.

[37] Wang X, Zhu X, Jiao S, et al. Cardiomyocyte peroxisome proliferator-activated receptor α is essential for energy metabolism and extracellular matrix homeostasis during pressure overload-induced cardiac remodeling. Acta Pharmacol Sin. 2022; 43(5):1231-1242. https://doi.org/10.1038/s41401-021-00743-z.

[38] Sunagawa Y, Kawaguchi S, Miyazaki Y, et al. Auraptene, a citrus peel-derived natural product, prevents myocardial infarction-induced heart failure by activating PPARα in rats. Phytomedicine. 2022;107:154457. https://doi.org/10.1016/j.phymed.2022.154457.

[39] Nishigaki A, Kido T, Kida N, et al. Resveratrol protects mitochondrial quantity by activating SIRT1/PGC‐1α expression during ovarian hypoxia. Reprod Med Biol. 2020; 19(2):189-197. https://doi.org/10.1002/rmb2.12323.

[40] Li FH, Huang XL, Wang H, et al. Protective effect of Yi-Qi-Huo-Xue Decoction against ischemic heart disease by regulating cardiac lipid metabolism. Chin J Nat Med. 2020; 18(10):779-792. https://doi.org/10.1016/S1875-5364(20)60018-8.